Table 2.
Demographic and clinical characteristics of study participants.
| Variables | All Patients n = 50 |
Non-Eosinophilic (Eosinophils < 4% and/or 300/μL) n = 29 |
Eosinophilic (Eosinophils 4% and/or 300/μL) n = 21 |
p Value |
|---|---|---|---|---|
| Sex, Male | 33 (66%) | 16 (55.2%) | 17 (81%) | 0.058 |
| Age, Years | 68 ± 8.9 | 68 ± 8.3 | 68 ± 9.9 | 0.989 |
| BMI, kg/m2 | 27 (23.8–29.8) | 24.5 (23.4–30.2) | 28.1 (24.8–29.8) | 0.371 |
| Smoker (N, %) | 32 (64%) | 18 (66%) | 13 (62%) | 0.629 |
| FEV1, Liters | 1.5 ± 0.51 | 1.44 ± 0.53 | 1.58 ± 0.46 | 0.343 |
| FEV1, % of predicted | 60.7 ± 18.9 | 61.1 ± 20.7 | 60.1 ± 16.7 | 0.862 |
| FEV1/FVC, % | 57.8 ± 11.9 | 57.9 ± 12.7 | 57.6 ± 11.1 | 0.922 |
| Comorbidities | ||||
| Coronary Artery Disease | 7 (14%) | 6 (20.7%) | 1 (4.8%) | 0.109 |
| Hypertension | 25 (50%) | 13 (44.8%) | 12 (57.1%) | 0.39 |
| Diabetes | 10 (20%) | 4 (13.8%) | 6 (28.6%) | 0.197 |
| Atrial Fibrillation | 5 (10%) | 2 (6.9%) | 3 (14.3%) | 0.39 |
| Ischemic Stroke | 5 (10%) | 2 (6.9%) | 3 (14.3%) | 0.39 |
| Heart failure | 2 (4%) | 1 (3.4%) | 1 (4.7%) | 0.815 |
| Cancer | 11 (22%) | 6 (20.7%) | 5 (23.8%) | 0.793 |
| Connective Tissue Disease (CTD) | 4 (8%) | 3 (10.3%) | 1 (4.7) | 0.473 |
| Therapy | ||||
| LAMA | 6 (12%) | 4 (13.8%) | 2 (9.5%) | 0.647 |
| LABA/LAMA | 15 (30%) | 10 (34.5%) | 5 (23.8%) | 0.416 |
| LABA/ICS | 4 (8%) | 1 (3.4%) | 3 (14.3%) | 0.163 |
| LABA/LAMA/ICS | 21 (42%) | 12 (41.4%) | 9 (42.9%) | 0.917 |
| No treatment | 4 (8%) | 2 (6.9%) | 2 (9.5%) | 0.735 |
Data are presented as mean ± standard deviation (SD) or median (interquartile ranges). p values indicate differences between the 2 groups. Abbreviations: BMI: body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; LAMA: long-acting muscarinic antagonists; LABA: long-acting β2-agonists; ICS: inhaled corticosteroids.